Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational ProductsGlobeNewsWire • 10/11/22
Allogene (ALLO) Begins Phase II Study on Allogeneic CAR T TherapyZacks Investment Research • 10/07/22
Allogene Therapeutics Initiates Industry's First Allogeneic CAR T Phase 2 TrialGlobeNewsWire • 10/06/22
Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine SummitGlobeNewsWire • 09/23/22
Allogene Therapeutics (ALLO) Down 10.9% Since Last Earnings Report: Can It Rebound?Zacks Investment Research • 09/08/22
Allogene Therapeutics, Inc.'s (ALLO) CEO David Chang on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Allogene Therapeutics (ALLO) Reports Q2 Loss, Tops Revenue EstimatesZacks Investment Research • 08/09/22
Allogene Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022GlobeNewsWire • 07/27/22
Allogene Therapeutics Appoints Scientific Pioneer Stephen Mayo to its Board of DirectorsGlobeNewsWire • 07/12/22
Allogene Therapeutics (ALLO) Moves 16.4% Higher: Will This Strength Last?Zacks Investment Research • 06/20/22
Allogene Therapeutics Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to ALLO-501A for Large B Cell LymphomaGlobeNewsWire • 06/08/22
Why Is Allogene Therapeutics (ALLO) Down 14.9% Since Last Earnings Report?Zacks Investment Research • 06/03/22
Allogene Therapeutics Announces Oral Presentation of Pre-Clinical Data Highlighting Improved Anti-Tumor Activity of Donor-Derived Allogeneic CAR T Cells at American Society of Gene and Cell Therapy (ASGCT) Annual MeetingGlobeNewsWire • 05/19/22
Allogene Therapeutics Named 2022 Bay Area “Best Place to Work” by San Francisco Business Times and Silicon Valley Business JournalGlobeNewsWire • 05/09/22
Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/05/22
Allogene Therapeutics Receives FDA Orphan-Drug Designation for ALLO-605, its First TurboCAR™ T Cell Product Candidate, for the Treatment of Multiple MyelomaGlobeNewsWire • 04/27/22
Allogene Therapeutics Unveils Cell Forge 1, a Uniquely Designed Manufacturing Facility to Deliver AlloCAR T™ ProductsGlobeNewsWire • 04/14/22
Allogene Therapeutics Announces Participation in Seven Upcoming Investor ConferencesGlobeNewsWire • 04/12/22